Kilitch Drugs (India) Limited has scheduled its 34th Annual General Meeting (AGM) for Thursday, August 27, 2026, at 9:00 am. The meeting will be conducted exclusively through video conferencing and other audio-visual means. This scheduling determines the timeline for shareholder voting and dividend entitlements for the financial year ended March 31, 2026.

The Board of Directors approved these arrangements during a meeting held on July 28, 2026, pursuant to Regulation 30 and Regulation 33 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board also approved the Directors’ Report and the Corporate Governance Report for the financial year 2025-26, along with all relevant annexures.

To ensure accurate determination of shareholders entitled to attend and vote, Kilitch Drugs will close its Register of Members and Share Transfer Books. The closure period runs from Thursday, August 20, 2026, to Thursday, August 27, 2026, both days inclusive. This action is taken in compliance with Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company appointed Mr. Deep Shukla, a Practicing Company Secretary, as the Scrutinizer for the AGM. He will oversee the entire voting process, including e-voting, and submit the report required for the declaration of results.

Key Dates and Appointments

Cost Auditor Reappointment

The Board reappointed M/s Arvind Kumar & Co., Cost Accountants, as the Cost Auditors of the company for the financial year 2026-27. The firm holds Registration No. 000646. The partner associated with the appointment is Mr. Arvind Kumar, who holds Membership No. 37904.

According to the disclosure, there is no relationship between the directors of Kilitch Drugs and the cost auditor. The firm’s area of experience includes accounts, taxation (including international taxation), ROC matters, internal audits, and cost audits.

Kilitch Drugs has commenced nutraceutical manufacturing at its new plant located in Village Maldev, Taluka Pen, District Raigad, Maharashtra on June 17, 2026. This operational expansion marks a significant milestone in the company's strategy to scale its presence in the nutraceutical segment.

Facility Details

The new manufacturing block is situated in the Raigad district of Maharashtra. The following table outlines the key parameters of the development:

Strategic Expansion

The commissioning of the Maldev facility represents a direct expansion of Kilitch Drugs' manufacturing capabilities. By establishing this new production block, the company aims to leverage the growing demand for nutraceutical products in India. This move underscores the company's commitment to enhancing its footprint in this specific category.